This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Effects of general practitioner training and family support services on the care of home-dwelling dementia patients–results of a controlled cluster-randomized study
Donath, Carolin,
Grässel, Elmar,
Grossfeld-Schmitz, Maria,
Menn, Petra,
Lauterberg, Jörg,
Wunder, Sonja,
Marx, Peter,
Ruckdäschel, Stephan,
Mehlig, Hilmar,
Holle, Rolf
Background: More than 90% of dementia patients are cared for by their general practitioners, who are decisively involved in the diagnosis, therapy and recommendation of support services.; Objective: To test whether special training of general practitioners alters the care of dementia patients through their systematic recommendation of caregiver counseling and support groups.; Method: 129 general […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Low-dose divalproex in agitated patients with Alzheimer’s disease
Adequate treatment of behavioral disturbances in Alzheimer’s disease is both important and difficult. This report describes a case series that examined the effectiveness and safety of low-dose divalproex in the treatment of agitated patients with Alzheimer’s disease who were admitted to an inpatient geriatric psychiatry unit over a 1-year period. All patients had agitation due […]
Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis
Cummings, Jeffrey,
Jones, Roy,
Wilkinson, David,
Lopez, Oscar,
Gauthier, Serge,
Waldemar, Gunhild,
Zhang, Richard,
Xu, Yikang,
Sun, Yijun,
Richardson, Sharon,
Mackell, Joan
To better characterize response to donepezil in patients with severe AD, Severe Impairment Battery (SIB) data were pooled from four donepezil clinical trials (N=904). Changes in SIB total and domain scores from baseline to week 24 were compared between placebo and donepezil treatment groups (observed case analysis). Analyses were stratified by baseline severity (Mini-Mental State […]
Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations
Cummings, Jeffrey,
Emre, Murat,
Aarsland, Dag,
Tekin, Sibel,
Dronamraju, Nalina,
Lane, Roger
Hallucinations in Alzheimer’s disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson’s disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two […]
Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants
A formula (formula F) was prepared to counteract oxidative stress (OS) in the brain. The formula contained the most common antioxidants and was intended to: (a) protect proteins, lipids, DNA and proteoglycans from oxidation (carnosine, coenzyme Q(10), vitamin E, vitamin C, beta-carotene, selenium, L-cysteine and ginkgo biloba); (b) reduce homocysteine (HCy) blood levels (vitamins B(6), […]
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer’s disease
Boche, Delphine,
Donald, Jane,
Love, Seth,
Harris, Scott,
Neal, James W.,
Holmes, Clive,
Nicoll, James A. R.
Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-beta (Abeta) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Abeta immunisation results in removal of Abeta from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Abeta42 […]